Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.

Bahap-Kara, Melda; Duran, Emine; Bayraktar-Ekincioglu, Aygin; Karadag, Omer

Bahap-Kara, Melda; Duran, Emine; Bayraktar-Ekincioglu, Aygin; Karadag, Omer.

Affiliation

Bahap-Kara M; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey. melda_610@hotmail.com.
Duran E; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Bayraktar-Ekincioglu A; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey.
Karadag O; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Intern Emerg Med ; 18(3): 791-799, 2023 04.

Article in En | MEDLINE | ID: mdl-36826744

Subject(s)

Agammaglobulinemia; Biosimilar Pharmaceuticals; Humans; Rituximab/adverse effects; Biosimilar Pharmaceuticals/adverse effects; Agammaglobulinemia/chemically induced; Agammaglobulinemia/drug therapy; Retrospective Studies; Treatment Outcome

Key words

Adverse events; Hypogammaglobulinemia; Infections; Infusion-related reactions; Interchangeability; Rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Agammaglobulinemia / Biosimilar Pharmaceuticals Type of study: Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: Intern Emerg Med Journal subject: MEDICINA DE EMERGENCIA / MEDICINA INTERNA Year: 2023 Type: Article Affiliation country: Turkey

Fulltext

XML

PubMed Links

Search on Google